Clinical trial · Interventional
Comparison of [68Ga]GaFAPI-46 PET/CT and [18F]FDG PET/CT Findings in Breast Carcinoma
NCT05339113CI-TRIAL-00059291unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to compare the diagnostic performance of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT in primary and metastatic lesions of breast cancer and to reveal the best diagnostic imaging time of 68Ga-FAPI-46 PET/CT.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Fibroblast Activation Protein Inhibitor | — | UNRESOLVED | — |
| Fluorodeoxyglucose F18 | — | UNRESOLVED | — |
| Positron Emission Tomography | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga-FAPI-46 PET/CT | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 68Ga-FAPI-46 PET/CT + 18-FDG PET/CT
- description
- 18FDG PET/CT scan is followed by \[68Ga\]FAPI-46 PET/CT within 2-3 days.
- interventionNames
- Diagnostic Test: 68Ga-FAPI-46 PET/CT
Primary outcomes (2)
- measure
- Maximum standardised uptake value [SUVmax] for primary lesion
- timeFrame
- 2-3 days
- description
- SUVmax of 68Ga-FAPI PET/CT for breast carcinoma in comparison with SUVmax value of 18F-FDG PET/CT
- measure
- Best diagnostic imaging time of 68GaFAPI-46 PET/CT
- timeFrame
- 2-3 days
- description
- Tumor-to-background ratio values measured over the 10th, 30th and 60th minute scan time
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * adult participants (aged 18 years or order); * participants with newly diagnosed breast carcinoma; * pathology confirmed by lesion tru-cut biopsy; * participants who were able to provide informed consent. Exclusion Criteria: * participants with non-malignant lesions; * participants with pregnancy; * the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.